Aminophylline hydrate

&#945-Cyclodextrin, sulfated sodium salt hydrate is a modified version of &#945-cyclodextrin, and is commonly used in the pharmaceutical industry to improve the solubility and bioavailability of poorly soluble drugs. Application

Application Glucose-1,6-bisphosphate and fructose-1,6-bisphosphate were used as bisphosphorylated glycan standards in mass spectrometry analysis to determine if pyrophosphate ions observed in lipid A from Gram-negative bacteria were artifacts

Application Glucose-1,6-bisphosphate and fructose-1,6-bisphosphate were used as bisphosphorylated glycan standards in mass spectrometry analysis to determine if pyrophosphate ions observed in lipid A from Gram-negative bacteria were artifacts

Application Glucose-1,6-bisphosphate and fructose-1,6-bisphosphate were used as bisphosphorylated glycan standards in mass spectrometry analysis to determine if pyrophosphate ions observed in lipid A from Gram-negative bacteria were artifacts

Application Glucose-1,6-bisphosphate and fructose-1,6-bisphosphate were used as bisphosphorylated glycan standards in mass spectrometry analysis to determine if pyrophosphate ions observed in lipid A from Gram-negative bacteria were artifacts

Application Glucose-1,6-bisphosphate and fructose-1,6-bisphosphate were used as bisphosphorylated glycan standards in mass spectrometry analysis to determine if pyrophosphate ions observed in lipid A from Gram-negative bacteria were artifacts

Other Notes Please note that Sigma-Aldrich provides this product to early discovery researchers as part of a collection of rare and unique chemicals. Sigma-Aldrich does not collect analytical data for this product.

Application BNTX, a selective nonpeptide &#9631 opioid receptor (DOR1) antagonist, is used in &#963 opioid receptor research to help differentiate and characterized the function and role of the &#9631 opioid receptor versus other &#963 opioid

Application BNTX, a selective nonpeptide &#9631 opioid receptor (DOR1) antagonist, is used in &#963 opioid receptor research to help differentiate and characterized the function and role of the &#9631 opioid receptor versus other &#963 opioid

Biochem/physiol Actions Potent, orally active, non-peptide B 2 bradykinin receptor antagonist. Features and Benefits This compound was developed by Novartis .

Biochem/physiol Actions Potent, orally active, non-peptide B 2 bradykinin receptor antagonist. Features and Benefits This compound was developed by Novartis .

Biochem/physiol Actions Metabolite of glycerophospholipid metabolism and phosphatidylethanolamine (PE) biosynthesis.